Provided are a microorganism having an ability to produce O-succinylhomoserine or succinic acid, and a method of producing O-succinylhomoserine or succinic acid by using the same.

Provided are a recombinant strain for preparing a terpenoid, and method for constructing the recombinant strain. Also provided is a recombinant bacterium 1, the recombinant bacterium 1 being a recombinant bacterium obtained in order to improve the enzymatic activity of α-ketoglutarate dehydrogenase in escherichia coli or the mutant thereof. The method for improving the enzymatic activity of α-ketoglutarate dehydrogenase in escherichia coli or the mutant thereof is replacing the original regulating element of the ketoglutarate dehydrogenase gene (sucAB) in escherichia coli or the mutant thereof with any of the following regulating elements: artificial regulating element M1-46, M1-37, and M1-93. Also provided are a plurality of recombinant bacteria. By improving the enzymatic activity of α-ketoglutarate dehydrogenase, succinic acid dehydrogenase and transaldolase therein and improving the ability of a cell to synthesize NADPH and ATP, the efficiency of the MEP pathway and the production capacity of terpenoid are improved.

Provided herein are microorganisms and methods for fermentative production of ß-ketoadipate from gaseous substrates such as carbon dioxide (CO.sub.2), carbon monoxide (CO), and/or hydrogen (H.sub.2). Additionally, the processes provided herein are methods for producing polymers containing ß-ketoadipate, that can potentially enable a circular economy by diverting waste, e.g., plastic waste.

The present invention relates to a novel strain of Trichoderma comprising genetic modifications that enable the improved production of an enzyme cocktail, involving at least upregulation of the transcription factor Xyr1 according to SEQ ID No. 1; disruption of the gene ACE1 according to SEQ ID No. 2; disruption of the gene SLP1 according to SEQ ID No. 3; and expression of the gene Cel3a from Rasamsonia emersonii according to SEQ ID No. 4.

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2′,6′-dimethyl-Tyr-D-Arg-Phe-Lys-NH.sub.2, Phe-D-Arg-Phe-Lys-NH.sub.2, or D-Arg-2′,6′-Dmt-Lys-Phe-NH.sub.2.

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2,6-dimethyl-Tyr-D-Arg-Phe-Lys-NH.sub.2, Phe-D-Arg-Phe-Lys-NH.sub.2, or D-Arg-2,6-Dmt-Lys-Phe-NH.sub.2.

A method for producing an L-amino acid such as L-glutamic acid is provided. An L-amino acid is produced by culturing a bacterium having an ability to produce an L-amino acid, which has been modified so that the activity of a non-PTS fructose-uptake carrier and the activity of fructokinase are both increased, in a medium containing fructose, and collecting the L-amino acid from the medium or cells of the bacterium.

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2,6-dimethyl-Tyr-D-Arg-Phe-Lys-NH.sub.2, Phe-D-Arg-Phe-Lys-NH.sub.2, or D-Arg-2,6-Dmt-Lys-Phe-NH.sub.2.

The present disclosure relates to a strain for producing L-glutamic acid and a method of use thereof.

A method for producing an L-amino acid such as L-glutamic acid is provided. An L-amino acid is produced by culturing a bacterium having an ability to produce an L-amino acid, which has been modified so that the activity of a non-PTS fructose-uptake carrier and the activity of fructokinase are both increased, in a medium containing fructose, and collecting the L-amino acid from the medium or cells of the bacterium.